Chris Cargill
Chief Executive Officer chez NXERA PHARMA CO., LTD.
Profil
Chris Cargill is currently the President, CEO & Representative Director at Nxera Pharma Co., Ltd.
since 2022.
He is also currently a Director at Sosei R&D Ltd.
since 2018 and a Director at Nxera Pharma UK Ltd.
since 2019.
Mr. Cargill completed his undergraduate degree at Monash University.
Postes actifs de Chris Cargill
| Sociétés | Poste | Début |
|---|---|---|
| NXERA PHARMA CO., LTD. | Chief Executive Officer | 24/03/2022 |
Sosei R&D Ltd.
 Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Director/Board Member | 01/06/2018 |
Heptares Therapeutics Ltd.
 Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Director/Board Member | 01/01/2019 |
Formation de Chris Cargill
| Monash University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 1 |
|---|---|
| NXERA PHARMA CO., LTD. | Health Technology |
| Entreprise privées | 2 |
|---|---|
Sosei R&D Ltd.
Sosei R&D Ltd. Pharmaceuticals: MajorHealth Technology Sosei R&D Ltd. manufactures pharmaceutical products. It develops and commercializes product opportunities based upon clinical uses for known drugs and templates. The company was founded by Julian Gilbert and Robin Bannister in March, 2000 and is located in Saffron Walden, the United Kingdom. | Health Technology |
Heptares Therapeutics Ltd.
Heptares Therapeutics Ltd. Pharmaceuticals: MajorHealth Technology Heptares Therapeutics Ltd. designs and develops new medicines targeting G protein-coupled receptors. It builts an exciting discovery and development pipeline of novel drug candidates, which have the potential to transform the treatment of serious diseases, including alzheimer's disease, parkinson's disease, schizophrenia, migraine and diabetes. The company was founded by Richard Henderson, Fiona Hamilton Marshall, Ludwig Michael Steinmetz, Christopher G. Tate and Malcolm Weir in 2007 and is headquartered in Welwyn Garden City, the United Kingdom. | Health Technology |
